Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

Stanley S SchwartzDiabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USAAbstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of developme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Schwartz S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Thiazolidinediones Pioglitazone insulin resistance type 2 diabetes insulin Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/33e4a4e1bbd24cc692ca6be2cb52a8c4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:33e4a4e1bbd24cc692ca6be2cb52a8c4
record_format	dspace
spelling	oai:doaj.org-article:33e4a4e1bbd24cc692ca6be2cb52a8c42021-12-02T06:49:56ZPioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin1178-7007https://doaj.org/article/33e4a4e1bbd24cc692ca6be2cb52a8c42010-07-01T00:00:00Zhttps://www.dovepress.com/pioglitazone-for-the-treatment-of-type-2-diabetes-in-patients-inadequa-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Stanley S SchwartzDiabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USAAbstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of development of type 2 diabetes. Insulin resistance leads to hyperinsulinemia in order to maintain normal glucose tolerance. In most cases of type 2 diabetes, beta-cell dysfunction develops subsequent to the development of insulin resistance, and it is not until such beta-cell dysfunction develops that any abnormality in glucose tolerance is seen. Insulin resistance is a primary defect in type 2 diabetes. The risk of coronary heart disease is significantly increased in patients with type 2 diabetes. Cardiovascular disease causes 80% of all diabetic mortality, and in 75% of those cases, it is a result of coronary atherosclerosis. These points provide a rationale for early and aggressive management of cardiovascular risk in patients with diabetes. Thiazolidinediones represent an effective tool for targeting some features of this increased risk as they decrease insulin resistance and can prevent and/or delay diabetes progression.Keywords: pioglitazone, type 2 diabetes, insulinSchwartz SDove Medical PressarticleThiazolidinediones Pioglitazone insulin resistance type 2 diabetes insulinSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 243-252 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Thiazolidinediones Pioglitazone insulin resistance type 2 diabetes insulin Specialties of internal medicine RC581-951
spellingShingle	Thiazolidinediones Pioglitazone insulin resistance type 2 diabetes insulin Specialties of internal medicine RC581-951 Schwartz S Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
description	Stanley S SchwartzDiabetes Disease Management at the University of Pennsylvania, Penn Presbyterian Medical Center, Philadelphia Heart Institute, Philadelphia, Pennsylvania, USAAbstract: Insulin resistance and impaired beta-cell function are primary defects that occur early in the course of development of type 2 diabetes. Insulin resistance leads to hyperinsulinemia in order to maintain normal glucose tolerance. In most cases of type 2 diabetes, beta-cell dysfunction develops subsequent to the development of insulin resistance, and it is not until such beta-cell dysfunction develops that any abnormality in glucose tolerance is seen. Insulin resistance is a primary defect in type 2 diabetes. The risk of coronary heart disease is significantly increased in patients with type 2 diabetes. Cardiovascular disease causes 80% of all diabetic mortality, and in 75% of those cases, it is a result of coronary atherosclerosis. These points provide a rationale for early and aggressive management of cardiovascular risk in patients with diabetes. Thiazolidinediones represent an effective tool for targeting some features of this increased risk as they decrease insulin resistance and can prevent and/or delay diabetes progression.Keywords: pioglitazone, type 2 diabetes, insulin
format	article
author	Schwartz S
author_facet	Schwartz S
author_sort	Schwartz S
title	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_short	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_full	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_fullStr	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_full_unstemmed	Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
title_sort	pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/33e4a4e1bbd24cc692ca6be2cb52a8c4
work_keys_str_mv	AT schwartzs pioglitazoneforthetreatmentoftype2diabetesinpatientsinadequatelycontrolledoninsulin
_version_	1718399683751051264

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin

Ejemplares similares